Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 355 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Powder Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00100295
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Hypericum perforatum, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2007 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assess the Effects of a 30 Day-wellness Program on Digestive Health, Weight and Overall Well-being

NCT06387251
View directory record Official record
Conditions
Digestive Health
Interventions
30 day wellness program
Other
Lead sponsor
Peryam & Kroll Research Corporation
Other
Eligibility
20 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 27, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

NCT05655819
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Glutamine, Placebo
Drug
Lead sponsor
David J. Cangemi
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

NCT05784363
View directory record Official record
Conditions
Enlarged Pores, Sebum Production
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 27, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

NCT00184548
View directory record Official record
Conditions
Acquired Bleeding Disorder, Trauma
Interventions
eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 27, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

NCT03221842
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
C1-esterase inhibitor, Placebo
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

NCT03580369
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab, Omalizumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
30
States / cities
Gilbert, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 27, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

NCT04524689
View directory record Official record
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Interventions
SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 27, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

NCT03093272
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate, Prednisone, Docetaxel, Apalutamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

NCT01414244
View directory record Official record
Conditions
Diarrhea-Predominant Irritable Bowel Syndrome
Interventions
Glutamine
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 72 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 27, 2026, 10:09 AM EDT
Withdrawn Not applicable Interventional

Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma

NCT00980551
View directory record Official record
Conditions
Retinoblastoma
Interventions
subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 3 Interventional Results available

A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder

NCT04504253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine monohydrate, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 2 Interventional Results available

ERG/5-HTP in Fragile X Syndrome (FXS)

NCT05030129
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
5-Hydroxytryptophan, Ergoloid Mesylates, Matching placebo for Ergoloid mesylates, Matching placebo for 5-Hydroxytryptophan
Drug
Lead sponsor
Elizabeth Berry-Kravis
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety

NCT00359801
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
132
States / cities
Bay Minette, Alabama • Fairhope, Alabama • Graysville, Alabama + 121 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Coffee Fruit Concentrate Pilot Study 1

NCT01965795
View directory record Official record
Conditions
Brain-derived Neurotrophic Factor (BDNF), Cognitive Function, Affect
Interventions
Whole Coffee Fruit Concentrate (WCFC), Nutrim
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 27, 2026, 10:09 AM EDT
Recruiting Phase 4 Interventional

Placement of Antibiotic Powder in Wounds During the Emergency Room

NCT03765567
View directory record Official record
Conditions
Open Fracture
Interventions
Vancomycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

NCT00700336
View directory record Official record
Conditions
Malignant Pleural Mesothelioma, Solid Tumors
Interventions
pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding
Drug
Lead sponsor
CanBas Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Not applicable Interventional Results available

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

NCT01828593
View directory record Official record
Conditions
HIV-associated Enteropathy
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 27, 2026, 10:09 AM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Polyphenols, Exercise, and Metabolomics

NCT01775384
View directory record Official record
Conditions
Exercise-induced Inflammation, Exercise-induced Oxidative Stress, Exercise-induced Immune Dysfunction
Interventions
Nutrasorb, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2013 · Synced Oct 27, 2026, 10:09 AM EDT
Completed Phase 1 Interventional

L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics

NCT01715844
View directory record Official record
Conditions
Asthma
Interventions
L-citrulline
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 27, 2026, 10:09 AM EDT